• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.改良ALBI分级在肝细胞癌患者肝功能更详细评估中的验证:一项多中心分析
Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.
2
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.白蛋白-胆红素分级在日本46681例肝细胞癌患者全国性调查中的验证、潜力及预后评估:对肝功能进行更详细评估的必要性
Liver Cancer. 2017 Nov;6(4):325-336. doi: 10.1159/000479984. Epub 2017 Sep 22.
3
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.白蛋白-胆红素分级对2584例日本肝细胞癌患者预后评估的价值
J Gastroenterol Hepatol. 2016 May;31(5):1031-6. doi: 10.1111/jgh.13250.
4
Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma.改良白蛋白-胆红素-TNM 评分作为评估肝细胞癌患者预后模型的验证
World J Hepatol. 2019 Jun 27;11(6):542-552. doi: 10.4254/wjh.v11.i6.542.
5
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.作为日本肝脏学会肝癌循证临床实践指南一部分的白蛋白-胆红素(ALBI)分级:与肝损伤及Child-Pugh分级的比较
Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846. Epub 2017 Mar 9.
6
A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade.通过改良白蛋白-胆红素(mALBI)分级对肝细胞癌患者的肝功能进行详细评估。
Am J Cancer Res. 2022 Jun 15;12(6):2711-2720. eCollection 2022.
7
Modified Albumin-Bilirubin Model for Stratifying Survival in Patients with Hepatocellular Carcinoma Receiving Anticancer Therapy.用于对接受抗癌治疗的肝细胞癌患者生存情况进行分层的改良白蛋白-胆红素模型
Cancers (Basel). 2022 Oct 17;14(20):5083. doi: 10.3390/cancers14205083.
8
Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.新提出的ALBI分级和ALBI-T评分作为评估肝细胞癌患者肝功能和预后的工具。
Liver Cancer. 2019 Oct;8(5):312-325. doi: 10.1159/000494844. Epub 2018 Nov 29.
9
Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade).基于改良的白蛋白-胆红素评分(ALBS 分级)提出的血清白蛋白作为仑伐替尼治疗肝细胞癌患者的预后因素的时序变化:白蛋白简化分级建议。
J Gastroenterol. 2022 Aug;57(8):581-586. doi: 10.1007/s00535-022-01883-7. Epub 2022 Jun 28.
10
Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade.30年间肝细胞癌患者肝脏基础功能的变化:Child-Pugh分级与白蛋白-胆红素分级的比较
Liver Cancer. 2020 Sep;9(5):518-528. doi: 10.1159/000507933. Epub 2020 Jul 16.

引用本文的文献

1
Proton Beam Therapy Provides Longer Survival and Preserves Muscle Mass in Hepatocellular Carcinoma Compared to TACE+RFA.与经动脉化疗栓塞术(TACE)联合射频消融术(RFA)相比,质子束治疗可使肝细胞癌患者获得更长生存期并保留肌肉质量。
Cancers (Basel). 2025 Aug 30;17(17):2849. doi: 10.3390/cancers17172849.
2
Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study.免疫疗法对不可切除的老年晚期肝细胞癌患者的影响:一项真实世界临床研究。
Cancer Med. 2025 Sep;14(17):e71171. doi: 10.1002/cam4.71171.
3
Inflammatory sarcopenia, a novel concept in chronic liver disease: insights from magnetic resonance imaging biomarkers.炎症性肌肉减少症,慢性肝病中的一个新概念:来自磁共振成像生物标志物的见解
Transl Gastroenterol Hepatol. 2025 Apr 23;10:50. doi: 10.21037/tgh-24-120. eCollection 2025.
4
Artificial intelligence for multi-time-point arterial phase contrast-enhanced MRI profiling to predict prognosis after transarterial chemoembolization in hepatocellular carcinoma.用于多时间点动脉期对比增强磁共振成像分析的人工智能,以预测肝细胞癌经动脉化疗栓塞后的预后
Radiol Med. 2025 Jul 24. doi: 10.1007/s11547-025-02043-6.
5
Combination of modified albumin-bilirubin grade and platelet count to predict high-risk varices in patients with hepatocellular carcinoma.改良白蛋白-胆红素分级与血小板计数联合用于预测肝细胞癌患者的高危静脉曲张
PLoS One. 2025 Jul 17;20(7):e0327967. doi: 10.1371/journal.pone.0327967. eCollection 2025.
6
Prognosis of Hepatectomy versus Systemic Chemotherapy Based on Oncological Resectability Criteria for Borderline Resectable Hepatocellular Carcinoma.基于临界可切除肝细胞癌肿瘤学可切除标准的肝切除术与全身化疗的预后
Liver Cancer. 2025 Jun 10. doi: 10.1159/000546830.
7
Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification.将ALBI分级与老年营养风险指数相结合可增强肝细胞癌风险分层。
Liver Cancer. 2024 Oct 5;14(2):193-210. doi: 10.1159/000541647. eCollection 2025 Apr.
8
Differential Prognostic Impact of Tumor Burden Score on Hepatocellular Carcinoma Patients with Variable Physical Performance Status.肿瘤负荷评分对不同身体状况的肝细胞癌患者的预后影响差异
Dig Dis Sci. 2025 Mar 28. doi: 10.1007/s10620-025-08971-7.
9
Hypozincemia Is Associated With Increased Tyrosine Levels, Low Handgrip Strength, Increased Incidence of HCC, and Liver Disease Progression-A Cross-Sectional Study.低锌血症与酪氨酸水平升高、握力降低、肝癌发病率增加及肝病进展相关——一项横断面研究
JGH Open. 2025 Mar 18;9(3):e70124. doi: 10.1002/jgh3.70124. eCollection 2025 Mar.
10
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.使用阿替利珠单抗和贝伐单抗进行一线免疫治疗的肝癌患者预后评分的评估
JHEP Rep. 2024 Dec 5;7(3):101295. doi: 10.1016/j.jhepr.2024.101295. eCollection 2025 Mar.

本文引用的文献

1
ALBI Score as a Novel Tool in Staging and Treatment Planning for Hepatocellular Carcinoma: Advantage of ALBI Grade for Universal Assessment of Hepatic Function.ALBI评分作为肝细胞癌分期和治疗规划的新工具:ALBI分级在肝功能通用评估中的优势
Liver Cancer. 2017 Nov;6(4):377-379. doi: 10.1159/000481212. Epub 2017 Oct 19.
2
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function.白蛋白-胆红素分级在日本46681例肝细胞癌患者全国性调查中的验证、潜力及预后评估:对肝功能进行更详细评估的必要性
Liver Cancer. 2017 Nov;6(4):325-336. doi: 10.1159/000479984. Epub 2017 Sep 22.
3
A better method for assessment of hepatic function in hepatocellular carcinoma patients treated with radiofrequency ablation: Usefulness of albumin-bilirubin grade.一种评估接受射频消融治疗的肝细胞癌患者肝功能的更好方法:白蛋白-胆红素分级的实用性。
Hepatol Res. 2018 Feb;48(3):E61-E67. doi: 10.1111/hepr.12927. Epub 2017 Aug 2.
4
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.作为日本肝脏学会肝癌循证临床实践指南一部分的白蛋白-胆红素(ALBI)分级:与肝损伤及Child-Pugh分级的比较
Liver Cancer. 2017 Jun;6(3):204-215. doi: 10.1159/000452846. Epub 2017 Mar 9.
5
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.《亚太地区肝细胞癌管理临床实践指南:2017年更新版》
Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. Epub 2017 Jun 15.
6
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.NS5A 耐药相关变异削弱了 ledipasvir 和 sofosbuvir 对感染 HCV 基因 1b 型肝硬化患者的疗效。
J Gastroenterol. 2017 Jul;52(7):845-854. doi: 10.1007/s00535-016-1290-1. Epub 2016 Dec 2.
7
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma.结合客观肝脏储备评估的改良CLIP对晚期肝细胞癌患者仍具有预后预测价值。
J Gastroenterol Hepatol. 2016 Jul;31(7):1336-41. doi: 10.1111/jgh.13312.
8
Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma.将白蛋白-胆红素(ALBI)评分纳入巴塞罗那临床肝癌(BCLC)系统用于肝细胞癌。
J Gastroenterol Hepatol. 2016 Jul;31(7):1300-6. doi: 10.1111/jgh.13291.
9
Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma.白蛋白-胆红素分级对2584例日本肝细胞癌患者预后评估的价值
J Gastroenterol Hepatol. 2016 May;31(5):1031-6. doi: 10.1111/jgh.13250.
10
Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus.日本糖尿病患者肝细胞癌的超声筛查
J Diabetes. 2016 Sep;8(5):640-6. doi: 10.1111/1753-0407.12340. Epub 2015 Nov 4.

改良ALBI分级在肝细胞癌患者肝功能更详细评估中的验证:一项多中心分析

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis.

作者信息

Hiraoka Atsushi, Kumada Takashi, Tsuji Kunihiko, Takaguchi Koichi, Itobayashi Ei, Kariyama Kazuya, Ochi Hironori, Tajiri Kazuto, Hirooka Masashi, Shimada Noritomo, Ishikawa Toru, Tachi Yoshihiko, Tada Toshifumi, Toyoda Hidenori, Nouso Kazuhiro, Joko Kouji, Hiasa Yoichi, Michitaka Kojiro, Kudo Masatoshi

机构信息

Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan.

Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan.

出版信息

Liver Cancer. 2019 Mar;8(2):121-129. doi: 10.1159/000488778. Epub 2018 Jun 11.

DOI:10.1159/000488778
PMID:31019902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6465715/
Abstract

BACKGROUND/AIM: The frequency of hepatocellular carcinoma (HCC) in patients with good hepatic reserve function has been increasing in Japan along with the progression of antiviral therapies and aging of the society. We evaluated the usefulness of modified albumin-bilirubin (ALBI) grade as a tool for assessment of hepatic reserve function.

MATERIALS/METHODS: We enrolled 6,649 naïve HCC patients treated from 2000 to 2017 and divided them into training (Ehime Prefecture group: E group, = 2,357) and validation (validation group: V group, = 4,292) cohorts. Child-Pugh classification and ALBI and modified ALBI (mALBI) grading were compared using with Japan Integrated Staging (JIS), ALBI-TNM (ALBI-T), and mALBI-T scores, which were calculated based on TNM stage and each assessment tool, retrospectively.

RESULTS

In the E group, Akaike's Information Criterion (AIC) and c-index values for mALBI-T (13,725.2/0.744) were better as compared to those of ALBI-T (13,772.6/0.733) and JIS score (13,874.7/0.720), with similar results observed in the V group (mALBI-T: 27,727.4/0.760; ALBI-T: 27,817.8/0.750; JIS: 27,807.5/0.748). Although there were some significant differences between the groups with regard to clinical background factors (age, etiology, tumor size, tumor number, treatment modalities), for all patients the AIC and c-index values of mALBI-T (45,327.1/0.755) were also better than those of ALBI-T (45,467.7/0.744) and JIS scores (45,555.8/0.739), indicating its superior stratification ability and prognostic predictive value in patients with HCC.

CONCLUSION

The detailed stratification ability of mALBI grade for hepatic reserve function is suitable for the recent trend of HCC patients, while mALBI-T may provide a more accurate predictive value than existing total staging scoring systems.

摘要

背景/目的:随着抗病毒治疗的进展以及社会老龄化,日本肝脏储备功能良好的肝细胞癌(HCC)患者的发病率一直在上升。我们评估了改良白蛋白-胆红素(ALBI)分级作为评估肝脏储备功能工具的实用性。

材料/方法:我们纳入了2000年至2017年期间接受治疗的6649例初治HCC患者,并将他们分为训练队列(爱媛县组:E组,n = 2357)和验证队列(验证组:V组,n = 4292)。回顾性地比较了Child-Pugh分类、ALBI和改良ALBI(mALBI)分级与日本综合分期(JIS)、ALBI-TNM(ALBI-T)和mALBI-T评分,后者是根据TNM分期和每种评估工具计算得出的。

结果

在E组中,mALBI-T的赤池信息准则(AIC)和c指数值(13725.2/0.744)优于ALBI-T(13772.6/0.733)和JIS评分(13874.7/0.720),V组也观察到类似结果(mALBI-T:27727.4/0.760;ALBI-T:27817.8/0.750;JIS:27807.5/0.748)。尽管各组在临床背景因素(年龄、病因、肿瘤大小、肿瘤数量、治疗方式)方面存在一些显著差异,但对于所有患者,mALBI-T的AIC和c指数值(45327.1/0.755)也优于ALBI-T(45467.7/0.744)和JIS评分(45555.8/0.739),表明其在HCC患者中的分层能力和预后预测价值更优。

结论

mALBI分级对肝脏储备功能的详细分层能力适合HCC患者的当前趋势,而mALBI-T可能比现有的总体分期评分系统提供更准确的预测价值。